Stage FocusSeed, Series A
GeographyUS
TypeVC
Last Activity2025
Industry Focus
Industries
Synthetic BiologyBiotechMedtech
Technical BenchStrong
Investor TypeDeepTech Purist
ExposureMostly DeepTech Investments
Bio
Newpath Partners was founded in 2018 by Tom Cahill, an MD/PhD physician-scientist who moved into investing. Fund II closed at $350M in December 2021 with a mandate to create life sciences companies, not just fund them.
The firm specializes in breakthrough biology platforms — gene editing and regenerative medicine in particular. The portfolio includes 13 companies, with 2 IPOs and 3 acquisitions (...
Notable Investments
P
Prime MedicineC
Chroma MedicineM
Myeloid TherapeuticsK
Kojin TherapeuticsE
Exo TherapeuticsSimilar Funds
CS
Carbon Silicon Ventures
San Francisco, United States
Pure DeepTechSynthetic BiologyBiotechMedtechPre-SeedSeed
Illumina Ventures
San Diego, United States
Pure DeepTechSynthetic BiologyBiotechMedtechSeedSeries A
The Production Board
San Francisco, United States
Pure DeepTechSynthetic BiologyAgritechBiotechPre-SeedSeed
a16z Bio + Crypto (Andreessen Horowitz)
Menlo Park, United States
GeneralistSynthetic BiologyBlockchainBiotechSeedSeries A
SOSV
New York, United States
Pure DeepTechSynthetic BiologyClimate TechRoboticsPre-SeedSeed
BC
Bioeconomy Capital
San Francisco, United States
DeepTech NativeSynthetic BiologyBiotechClimate TechSeedSeries A